Genome-wide association studies are transformative in revealing the polygenetic basis of common diseases, with autoimmune diseases leading the charge. Although the field is just over 10 years old, advances in understanding the underlying mechanistic pathways of these conditions, which result from a dense multifactorial blend of genetic, developmental and environmental factors, have already been informative, including insights into therapeutic possibilities. Nevertheless, the challenge of identifying the actual causal genes and pathways and their biological effects on altering disease risk remains for many identified susceptibility regions. It is this fundamental knowledge that will underpin the revolution in patient stratification, the discovery of therapeutic targets and clinical trial design in the next 20 years. Here we outline recent advances in analytical and phenotyping approaches and the emergence of large cohorts with standardized gene-expression data and other phenotypic data that are fueling a bounty of discovery and improved understanding of human physiology.
A transformative era has begun of big data, large consortia and cohorts, landscape-changing phenotyping tools, including single-cell genomics, genome-wide association studies (GWASs) of numerous traits and diseases, and a multitude of statistical and computational methods and approaches. Here we consider some aspects of analysis and causal-gene discovery and highlight some exceptional recent advances, from the perspective of a classic autoimmune disease, type 1 diabetes (T1D). The field of the genetics of common multifactorial diseases is moving rapidly toward the identification of causal genes and pathways and away from concern about 'missing heritability' , which for T1D was a red herring, since a polygenic model fits well for T1D, explaining most familial clustering (in terms of sharing of disease diagnosis of siblings (λ s ), which is the ratio of disease risk for a person who has a sibling with the disease to the disease risk of the general population) 1 . Explaining λ s took an exciting leap forward through analyses of families, showing that untransmitted parental alleles can have a significant effect on the characteristics of the children and in determining the sharing of traits between siblings 2 . Exome and whole-genome sequencing of vast numbers of patients and population cohorts will reveal very rare (<0.1%) disease-associated variants that will help pin down which genes are causal.
The importance of an adequately large sample size
An increase in sample sizes in large consortia has enabled the discovery of hundreds of chromosomal regions associated with autoimmune diseases that was previously not possible 3, 4 and has also reduced overestimation of effect sizes, the so-called 'winner's curse' (Box 1), owing to greater statistical power. For example, in the latest genetic analysis of rheumatoid arthritis (RA), over 100,000 subjects were analyzed, of which 29,880 were patients (cases), and 101 regions associated with RA were identified 5 . Similarly, for inflammatory bowel disease (IBD), an analysis of 95,000 subjects (42, 950 cases) identified 38 previously unknown risk loci 6 , which brought the total number of regions associated with IBD to 232. A smaller study of IBD with almost 60,000 subjects (25,042 cases) 7 , but with a greater proportion genotyped with a genome-wide platform rather than with the ImmunoChip, an immune-disease-region-targeted single-nucleotide polymorphism (SNP) microarray, identified further associated regions, which took the total number up to 240.
GWAS is a triumph of statistical correction for multiple testing in which reported regions must pass a P-value threshold of <5 × 10 −8 , which ensures that the majority of declared regions are true effects. The same rigor is not yet applied to biological and '-omics' or genome-wide phenotyping studies, since many factors are not yet understood, such as the complexity and extent of gene expression, epigenetic modification (including DNA methylation), non-coding RNA expression, gene splicing, or post-translational protein modification, all of which could generate over 50,000 functional DNA elements and over 250,000 proteins. This huge 'statistical space' is amplified even more by the proven but largely unexplored interactions among the human genome, its physiology and variation in microbial metabolism and immune-system reactivity, which could herald a new era of irreproducibility 8 . Each region might have more than one causal gene and variant, which could be a SNP, a repeat sequence or a structural variant such as an inversion. In T1D, a combination of GWAS 9 and use of ImmunoChip 10 in fewer than 10,000 cases has identified almost 60 associated regions (detailed in the curated database at https:// www.immunobase.org/). It is apparent how increasing the number of cases of type 2 diabetes (T2D) from 1,924 cases 11 to 74,124 cases 12 has increased the number of associated regions from 3 to 243, so genotyping of more cases of T1D can be expected to identify many previously unknown regions and explain a greater proportion of the genetic variance of T1D. With GWAS data from population-based cohorts available now, controls are not limiting (although caution is recommended, as discussed below). The index or lead variants in these regions can be combined in a genetic risk score (GRS) or polygenic risk score. The GRS can be used to identify those at greatest risk of disease, which can be used to select children from the general population for prevention trials 13 , to distinguish T1D diagnosed later in life from T2D 14 or to predict disease severity 15 . In the UK Biobank health resource 16 , for example, plasma and DNA samples from people with the very most extreme GRSs for the most common diseases but not yet affected by the disease under analysis could be used to identify early precursors of the disorder (or genetically validated biomarkers).
Even the sizes of the largest disease GWASs are modest relative to those of population cohort resources such as the UK Biobank and the 23&me cohort 17, 18 , which will be crucial in establishing disease . There is incredible scope for making many new discoveries with hundreds of thousands of people in these collections, which link medical records with lifestyle, biomarkers and GWAS data, and this will result in an avalanche of new findings 20 and preprints in BioRxiv (https://www.biorxiv.org). For some diseases, such as T1D, these research returns will be tempered by a low disease prevalence and/or ascertainment biases exacerbated by disease severity.
However, with large sample sizes there also comes a risk of detecting false-positive associations; if not accounted for, seemingly small confounding effects can make a huge difference. For example, the UK Biobank found that almost 150,000 people were related by at least a third degree 21 . Using linear mixed models, employing a genetic relatedness matrix as a random effect can be an effective way of analyzing data from related people and should be considered in these circumstances 22 . Another consideration for the use of resources of this kind, particularly in attempts to identify diseaseassociated variants, is the ratio of cases to control subjects. Even 'common' autoimmune diseases are generally quite rare, relative to the incidence of, for example, T2D, and there will probably be a large imbalance in the number of control subjects to the number of cases, which can lead to high rates of type 1 errors (false-positive results) 23 . Including only those control subjects who have been very precisely matched to cases on the basis of a large number of demographic and clinical characteristics would reduce heterogeneity and ensure a more balanced design. The multiple-testing 'ogre' raises its head again and must be accounted for appropriately in analyses of thousands of phenotypes in a genome-wide fashion.
Fine mapping of candidate causal variants
Identifying the causal variant driving the disease association is complicated by linkage disequilibrium (LD). This correlation between nearby SNPs, which occurs as a result of SNPs' being passed down from parent to offspring on the same haplotype (ref. 24 provides a more detailed explanation and example), makes it difficult to determine which SNP among an LD block is the causal one. Large sample sizes are critical for reducing the number of candidate DNA variants that could be causal within a region, referred to as the 'credible set' . The more cases and controls included, the more rare recombinant chromosomes analyzed, thus driving the resolution of the fine mapping. Ethnically diverse populations can be an advantage here, because they have different patterns of LD or arrangements of alleles on individual chromosomes or haplotypes. Nevertheless, considerable care must be taken in meta-analyses of diverse populations, and several methods for this have been developed 6, 25, 26 . When access to individual-level genotype data is available, and there is still an urgent need to provide these data to allow the accurate assembly of haplotypes, and the population being studied is homogeneous in terms of ancestry, a reasonable starting point for fine mapping is to use a simple stepwise linear-regression approach. This was performed in the T1D ImmunoChip analysis, in which three regions (near INS, PTPN2 and TYK2) were found to have two independent signals associated with T1D, while two regions (near IL2RA and IFIH1) were found to have (at least) three independent signals 10 . However, there are two potential problems with this approach. The first is identifying an appropriate P-value threshold at which to stop the procedure; such a threshold is not directly comparable between studies, as the P value is heavily influenced by the power of the dataset. Bayesian approaches such as the 'probabilistic identification of causal SNPs' 27 can help overcome this problem by generating posterior probabilities of association that are comparable across datasets. The second challenge is that the index SNP could be tagging two disease-associated haplotypes; in such cases, the stepwise regression approach would identify the SNP that tags the two haplotypes as the lead or index variant, while the two risk haplotypes might not be detected, which would lead to a misleading number of signals detected in the region. For this reason, approaches that search for combinations of SNPs with the most evidence of association, rather than assuming the index SNP is associated, are sometimes more appropriate. GUESSFM 28 is one such approach and has provided evidence of two independent SNP associations (rs61839660 and rs41295055) at the IL2RA region that are associated with multiple sclerosis (MS), whereas stepwise regression detects only one signal (rs2104286), the more commonly reported SNP for this region, which probably tags the two risk haplotypes and therefore is not a primary candidate as a causal variant. In contrast, rs61839660 almost certainly is a causal variant that alters expression of IL2RA (which encodes the CD25 subunit of the cytokine IL-2 receptor 24, 29 ) and alters the sensitivity of regulatory T cells to IL-2, which is required for their maintenance and function in preventing autoimmunity. When only summary association statistics, not raw data, are available, various methods that have been developed, including CAVIARBF 30 , FINEMAP 31 and JAM
32
, can be used to fine map regions, although challenges remain for these approaches 33 .
Pleiotropy: genetic variation can affect multiple diseases
Since autoimmune diseases and other immune diseases share many common variants, referred to as 'pleiotropy' , several studies have combined data from multiple diseases in order to increase power of detecting novel loci not previously associated with disease. A joint GWAS meta-analysis of asthma, hay fever and eczema (in 180,129 cases and 180,709 control subjects), as allergic diseases that share a common genetic etiology, identified 99 regions (73 were previously unknown, and only 4.4% were specific to one of the three diseases) 18 . Notably, the study named six candidate causal genes, including CCR7, which raised the possibility of repositioning existing drugs, originally developed for other diseases, for which the effect on expression of the allergy-protective allele and existing drug matched. This pleiotropy extends to T1D, and several of the candidate genes are shared, including the CLEC16A-DEXI region, ERBB3, IL2RA, BACH2, IL7R, FASLG, SH2B3, TNFAIP3 and PTPRK. The PTPRK-THEMIS region, for example, has been associated specifically with T1D diagnosed in patients under 5 years of age and encodes molecules with a function in the thymus 34 , specifically in T cell development early in life during the production of recent thymic emigrants 35 . Once again, however, this region shows the now commonly expected complexity, with an association for MS with an index SNP, rs802719 36 , that is not in LD with the lead age-at-diagnosis SNP for T1D, rs72975913, notwithstanding results from studies of T1D indicating more than one association signal in the region 34 . Another example is the functional missense SNP in IL6R, which provides protection from RA, T1D and cardiovascular disease but results in predisposition to allergic disease 37 , indicative
Box 1 | Winner's curse
Many identifications of genetic associations have not been replicated in subsequent studies. The reason for this is usually a lack of statistical power, which leads to inflated estimated effect sizes of truly associated SNPs as well as false-positive associations. Inflation in effect sizes in underpowered analyses of SNPs occurs because studies will typically report SNPs associated below a particular P-value threshold. If the analysis is underpowered, then the effect size at the declared associated SNP will need to be higher by chance than its true value in order to compensate for the lack of power. This distortion in effect sizes is called the 'winner's curse' 160 , since the first time an association is detected it probably has a larger estimated effect than the actual value. However, if replicated in a study that has been powered appropriately, the estimated effect size will probably better reflect the real effect of the variant.
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of a possible contraindication for the use of existing antagonist drugs directed against IL-6R in certain patients (for example, children with a very high GRS for allergic disease). A further example of opposite associations can be seen for IL7R and is illustrated in UK Biobank using the GWAS summary statistics for allergic disease and related phenotypes, such as eosinophil count (Global Biobank Engine, https://gbe.stanford.edu) versus the association with a number of autoimmune diseases, including MS 38 : the minor C allele of rs6897932 results in predisposition to autoimmunity and provides protection against allergic disease.
Typically, as with many autoimmune diseases, only a small proportion of the index or sentinel SNPs associated with allergic diseases are coding SNPs (22 of 132, or 16.7%) 18 . The importance of epigenetic variation, either associated with a disease-associated variant or independent, is highlighted by the finding that for 36 candidate genes for allergic diseases, CpG methylation (associated with lower promoter activity) influences transcription independently of genetic effects. We note, however, that methylation might not be the primary event in the altered transcriptional regulation but, instead, it might be a consequence of transcription-factor binding, in which methylation has a role for the maintenance of a transcriptional state 39 .
Mendelian randomization
Mendelian randomization (MR) studies combine GWAS data from different traits in order to draw conclusions about one trait's acting as a causal risk factor for another trait (Box 2). As so many summary statistics for a wide range of potential intermediate phenotypes and diseases (such as those at https://www.ebi.ac.uk/gwas/ or http://www.gwascentral.org) are publically available, it is possible to perform MR studies for many different intermediate traits and a multitude of different diseases. An example of the application of MR analysis to an autoimmune disease is the link between vitamin D and MS, with two separate publications demonstrating that decreased levels of vitamin D are causally associated with an increased risk of MS 40, 41 , which provides evidence in support of the epidemiological observation that low levels of vitamin D might increase susceptibility to MS.
However, MR uses three central assumptions, which must all be considered carefully before MR studies are undertaken 42 . First is the assumption that the SNP(s) of interest is (are) associated with the exposure variable (for example, level of vitamin D). This assumption is usually not violated and is often a reason to conduct the MR study in the first place. Second is the assumption that the SNP(s) of interest is (are) not associated with any confounding variables. This assumption has been put under threat by the finding that untransmitted alleles in families can affect characteristics and phenotype of the children, such as educational attainment 2 , a point that is echoed in ref. 43 . In addition, it is now known that methylation can alter the function of a SNP 44 , which is another way that a SNP under consideration could be associated with a confounding variable and violate the second assumption. Finally, the third assumption is that the SNP(s) of interest affect(s) the outcome (for example, MS) only through the exposure variable (for example, level of vitamin D). This is the point at which pleiotropy can become problematic, since the SNP(s) under consideration could be affecting various traits that are, in turn, affecting disease risk. There are two types of pleiotropy: vertical and horizontal. Horizontal pleiotropy, in which the SNP(s) affect(s) two or more separate traits, is the kind that can violate MR assumptions. Vertical pleiotropy refers to situations in which the variant affects one trait and this results in changes to other traits. An additional concern in the use of MR is that it has been shown that if there is measurement error in the phenotype analysis, the effect direction from MR analyses can appear to be the opposite from what is truly the case, although methods have been developed to counter this potential problem 45 . Caution should therefore be taken in MR studies 46, 47 , and there should always be very careful consideration that the assumptions of MR are not violated in the use of the approach.
Decoding the non-coding genome
Since the majority of disease-associated SNPs identified by GWASs are located in non-coding regions (which includes non-coding RNAs), the challenge remains of identifying the target gene(s) or non-coding RNA(s), tissue specificity and mechanisms via which causal variants drive disease susceptibility, even when disease association has been narrowed down to a single variant in a region 29 .
Technological advances in DNA and RNA sequencing and analytics combined with novel methods have provided the platform for large efforts such as the ENCODE 48 , BLUEPRINT 49 , ROADMAP 50 and FANTOM 51 consortia. Functional annotation of the genome, including but not limited to the mapping of post-translational histone modifications, transcription factor-binding sites, CpG methylation and areas of open chromatin and the use of massively parallel reporter assays, has revolutionized the ability to understand the 'grammar' of the non-coding genome and the mechanisms underpinning variation in gene expression 52, 53 . Landmark studies detailing genome-wide screens of open regulatory areas of chromatin (DNase I-hypersensitivity sites) provided evidence that common variants can alter chromatin accessibility and local gene expression 54 and that DNase I-hypersensitivity sites show enrichment for autoimmune disease-associated SNPs 55 . Subsequent studies detailed enrichment for autoimmune disease-associated SNPs in enhancers and clusters of enhancer elements, or 'super-enhancers' , in T cells 56, 57 . The finding of enrichment for disease-associated SNPs in enhancers, key regulatory elements of genes that govern the lineage and functional state of cells through tissue-specific and temporal control of gene transcription, provided the initial biological framework linking common disease-associated SNPs, enhancers and regulation of gene expression. Methods have been developed to integrate functional annotation data with GWAS summary statistics to prioritize variants that lie in annotations that show enrichment for 'disease hits' in disease-relevant cell types 27, [58] [59] [60] . The application of this information to the understanding of the genetic etiology and cell specificity of autoimmune-disease association has been
Box 2 | Mendelian randomization
Mendelian randomization (MR) aims to deduce the causality of an intermediate phenotype (for example, vitamin D levels) on an outcome (for example, MS) 40, 41 by using the SNPs associated with the intermediate phenotype, referred to as 'instrumental variables' , to obtain predicted levels by genotype. These predicted levels of the intermediate phenotype should be independent of any confounding factors, since confounding effects should, by chance, be evenly distributed among the genotype groups, given the random allocation of genotypes from parents to offspring. These predicted levels of the intermediate phenotype are then regressed against the outcome of interest in order to assess the association between the genetically controlled variation in the intermediate phenotype and the outcome. The procedure is analogous to a randomized control trial, such as two groups randomized to either high doses of vitamin D or placebo. In a simple MR setting, this could be the major and minor homozygotes at a SNP that is known to affect vitamin D levels. In the clinical trial setting, randomization would occur in order to minimize the chances of observing spurious associations due to confounding factors; in the MR setting, this randomization has already occurred at birth. The main text outlines the fundamental assumptions in MR that are required and need to be considered carefully. Another example of a successful MR study linked branched-chain amino acids to T2D . These methods are effective in guiding the most likely variants, on average, but also require cautious interpretation, since not all disease-associated SNPs will lie in the same type of annotation, the same cell type or the same cellular activation or differentiation state (Fig. 1) .
Once regions are identified as being disease associated, follow-up studies are launched to identify the mechanism through which the variant alters disease susceptibility. It is common for 'expression of quantitative trait loci' (eQTL) studies to be carried out, using many fewer individual samples than those in GWASs, but ideally from purified disease-relevant primary cell populations. The choice of disease-relevant cell types is challenging and, hence, autoimmunedisease-focused eQTL studies have so far used a limited number of purified cell types, usually the following common blood cells: CD4 +
T cells, CD8
+ T cells and monocytes 62 . Thus, the chance of identifying a candidate causal gene (from a GWAS) that overlaps an eQTL depends to varying degrees on the following: (a) the appropriate cell type and its state of activation being measured, which could be a population of cells in a mixture of cells, such as B cells among peripheral blood mononuclear cells; and (b) sufficient numbers of subjects in the study to detect the difference (Box 3). Nevertheless, large resources such as the Genotype-Tissue Expression project (https://www.gtexportal.org/home/), whole-blood analyses (for example, https://molgenis58.target.rug.nl/biosqtlbrowser/) and the Immune Variation project 63 have been and will be extremely useful in generating and collating eQTL data for multiple tissues and under multiple conditions, but there are still many different cell types under many different conditions that can be studied. For example, a particular variant associated with an autoimmune disease might increase disease susceptibility when present in activated CD4 + T cells but not when present in non-activated CD4 + T cells (Fig. 1) . Furthermore, occasionally, results differ between studies in terms of the direction of effect of the eQTL, such as results for the T1D candidate gene UBASH3A, with differences arising from the presence of very small amounts of mRNA in a particular cell type when a complex mixture of cells is analyzed (such as a T cell-specific gene in whole blood) 64 . It is apparent that establishing the causal tissue or cell type is an important step that must be undertaken before the candidate causal gene is declared solely on the basis of eQTL or allele-specific expression studies 65 ; the eQTL must be in the cell type that is altering disease susceptibility in that region. The ability to assess gene expression in single cells will also substantially boost allele-specific expression analyses and will also help define the heterogeneity and functions of cell types within tissues 66, 67 . Developments in proteomic technologies now offer the ability to measure the levels of thousands of intracellular and plasma proteins 68, 69 , which will provide an emerging wealth of genetic associations with protein abundance (protein QTLs) 68 . Another important aspect of fine mapping and causal gene-variant identification is the integration of expression data or functional 'readouts' associated with the credible SNPs, an approach used to help delineate the IL2RA region 28 . Underpinning this integration is the ability to obtain reliable genotype-to-phenotype data from specific cell types, and this goal is greatly enhanced by the availability of large bioresource 
T cells (Non-activated CD4) and activated CD4
+ T cells (Activated CD4); unpublished data) and with the published chromatin-conformation-capture PCHi-C data 79 (bottom; activated CD4 + T cells and non-activated CD4 + T cells) representing promoter-interacting regions (PIRs)) reduces the number of SNPs (n = 208) to a number that can be explored experimentally (n = 14). CD4 + T cells were chosen for this analysis because we observed the greatest enrichment for T1D SNPs in enhancers in these cells, as well as in B cells, CD8
+ T cells and CD34 + stem cells 10 , which indicates that these cells are a major T1D-associated cell type in the blood. The importance of investigating different CD4 + T cell-activation states is highlighted by the ATAC-seq and PCHi-C datasets. No PIRs overlapping the credible SNP sets were detected above threshold for the protein-coding genes KIAA1109, IL21 and ADAD1 in CD4 + T cells in the region; therefore, they are not considered candidate causal genes in this cell type. Two activation-induced interactions extend from the promoter of IL21-ASI ('anti-sense non-coding transcript') into the gene body of KIAA1109 and overlap disease-associated SNPs but not open chromatin. The intergenic region between IL2 and IL21 shows enrichment for activation-dependent PIR contacts (below plot: thicker and darker lines represent higher CHiCAGO scores and thus represent more interactions between a promoter and a PIR in a given cell population 78 ) that intersect with activation-induced open chromatin and link to the IL2 promoter. Therefore, IL2 is considered the strongest candidate causal gene in this region in this cell type under these conditions. These results justify further detailed investigation of chromosome conformation with methods of higher resolution, such as Capture-C 81 , gene and regulatory-region transcript expression 79 and mutagenesis of specific variants coupled to detailed haplotype mapping 24 . Chr4, chromosome 4; hg19, human genome version 19.
. While the lower sample size seen in functional studies is a necessary compromise for feasibility, studies would benefit greatly from pre-study power calculations for the main outcome of interest based on small pilot studies, which would advance such research one step further on the road to tackling the widespread crisis of reproducibility in experimental biology (Box 3).
Physical linking of credible risk-variant candidates to candidate causal genes
The development of chromosome-conformation-capture techniques to determine the three-dimensional structure of chromatin structure 72 has allowed the linkage of regulatory elements such as enhancers containing disease-associated SNPs to their target genes. A seminal study investigating obesity-associated variants in the FTO region of chromosome 16q12.2 73 and application of the targeted chromosome-conformation-capture technique to the T1D region 16p13.13 74 identified IRX3 and DEXI, respectively, as candidate causal genes, alongside FTO and CLEC16A, previously considered the candidate genes simply because they are nearest or contain the most disease-associated SNPs. Application of the chromosomeconformation-capture technique, therefore, challenges the practice of nominating candidacy to the nearest or most biologically plausible candidate in a disease-associated region. Iterative improvements in genome-wide chromosome-conformation-map resolution using the Hi-C method 75, 76 have enabled resolution of chromatin interactions to 750 base pairs 77 and have provided insight into the principles of chromatin organization and control of gene expression. However, the application of Hi-C to the linkage of regulatory DNA elements containing disease-associated SNPs to their targets is confounded by the onerous need for a large number of cells and billions of sequencing reads per sample to attain the high-resolution maps required for interpretation. Alternative genome-wide methods have therefore been developed and utilized to identify candidate genes through the use of targeting approaches such as
Box 3 | Sample-size calculations and statistical power
Sample-size calculations are essential for answering almost all scientific questions in a robust manner. We illustrate this with an example of a microarray sample-size-calculation method 162 using data from the ArrayExpress archive of functional genomics data (accession code E-MTAB-4852). The example provided here (left) shows the median proportion of false discoveries after 1,000 simulations at each sample size (horizontal axis) and each P-value threshold for significance (key). This method assigns groups randomly to each subject and sets the effect size for the truly associated transcripts; from here we can work out the proportion of truly associated transcripts called 'significant' and the proportion of false-positive results, since it is known which are the true associations. It can be observed that choosing a significance threshold of P = 0.001 will result in >60% of 'significantly' associated transcripts being false-positive associations, as a result of the large number of transcripts analyzed (>30,000). Decreasing the P-value threshold to 1 × 10 −4 is more stringent, and the proportion of false-positive associations decreases. Having a more stringent P-value threshold increases the probability of missing truly associated transcripts, so sample-size calculations should be based on minimizing the probability both of detecting false-positive associations and of missing true associations. The required sample size is dependent on the question to be answered (figure, right): attempting to detect a tenfold difference in transcript expression will require fewer subjects than attempting to detect a twofold difference will, since the effect size is much larger and is thus less likely to be observed by chance. It is also true that the false-negative rate is higher if the effect size is twofold than if it is tenfold, if the study is underpowered. Therefore, having an estimate of the anticipated effect size is critical during experimental design. It is then possible to include enough subjects or samples in the experiment to detect this difference in a robust and reproducible manner, as illustrated in a published transcriptome profiling study distinguishing different subsets of human naive T cells 35 . A detailed exploration of sample size in eQTL studies is provided in ref. 160 .
. The finding of networks of interactions in each cell type has confirmed the role of distal enhancers in transcriptional control of gene promoters in determining hematopoietic cellular identity 78 , the activation of CD4 + T cells 79 and differentiation state 83 . In confirmation of the enrichment for disease-associated SNPs in T cell enhancers, studies have shown enrichment for T1D-associated SNPs in promoter-interacting regions in T cells 78 , activation-induced interactions in CD4 + T cells 79 and enhancer interactions insubsets of CD4 + T cells 83 . The complexity of gene regulation is highlighted in each experimental approach; for example, enhancers can interact with multiple gene promoters, 'skip' multiple gene promoters and switch target promoters after activation or differentiation. For T1D, integration of the genome-wide analysis of both the fine-mapping ImmunoChip dataset 10 and imputed GWAS dataset 9 with the PCHi-C datasets 78, 79 has demonstrated the utility of linking promoters with their regulatory partners in extending understanding of the genes involved in T1D. Novel candidate genes in 29 T1D regions have been prioritized by this approach, in addition to those already nominated as candidates (Table 1) . Genes in four regions that previously had no named candidate gene (for example, 22q12.2 and LIF) and multiple genes with good candidacy in regions with an established candidate gene have been prioritized (for example, 1q32. 1 79 ). New plausible candidate genes, in regions in which the biological relevance of the incumbent gene to the etiology of T1D was not appreciated, have also been identified 10 (for example, 10q23.31; newly identified candidate gene PTEN). In-depth exploration of each region and different experimental approaches 24, 79, 84, 85 will be needed to delineate regions for which multiple genes have been prioritized in different cell subsets, differentiation and/or activation states and different cell types.
For example, one alternative approach that does not require chromosome-conformation information used a statistical model involving MR and information about open chromatin and gene expression from 100 genotyped people. This study identified over 15,000 putatively causal interactions between distal regions of open chromatin, and over 60% of these interactions were over a distance of less than 20 kilobases. Because the authors were able to infer the direction of causal interactions, the model also substantially improved finemapping ability; when applied to an eQTL dataset, the number of variants in the 90% credible set size was reduced by half 86 .
Infection, the microbiome and genes
Environmental exposures such as infection have been proposed to elicit the development of autoimmune disease in at-risk people [87] [88] [89] [90] [91] ; therefore, it is of interest to compare GWAS results for infectious diseases. Selective pressure by infectious diseases has driven the development of high inter-individual variability in genes encoding immune system-related molecules, especially in the highly polymorphic human major histocompatibility complex (MHC) region 92 . Genes encoding HLA class II and I molecules in the MHC region have by far the greatest genetic effect on the risk of developing T1D 93, 94 and, as might be expected, the HLA region is associated with susceptibility to common infections 88 . In contrast to the GWAS 'bonanza' for autoimmune disease, the GWAS approach has, until recently, yielded few susceptibility regions for infectious diseases. However, the very large data-rich population cohorts 16, 95, 96 are transforming the ability to gain insight into the overlap between the genetics of common infections and autoimmune disease. For example, several variants associated with susceptibility to common infections overlap T1D disease-associated regions (specifically, regions containing HLA, FUT2, SH2B3, IKZF1 and SBK1) 17 . Notably, the enzyme FUT2 (α (1,2)-fucosyltransferase 2), which is expressed in secretory epithelia, including the salivary glands, small intestine and colon, mediates the transfer of fucose to the terminal galactose on glycan chains of cell-surface glycoproteins and glycolipids 97 . FUT2 creates disaccharides with Fucα (1,2)Gal linkages, called the 'H antigens' , which can be left unmodified or can be converted into A antigens or B antigens or both, depending on the person's ABO blood group 97 . These antigens are referred to as 'histoblood group antigens' and, when present on the intestinal epithelium and in mucosal secretions, can serve as nutritional sources and as receptors and attachment sites for microorganisms, parasites and viruses and can thereby influence host-microbe interactions 98, 99 and the composition of the microbiome [100] [101] [102] [103] [104] . The 20% of Europeans known as 'non-secretors' are homozygous for an enzyme-inactivating nonsense allele (W134X; rs601338 G>A) of the gene encoding FUT2 and thus lack histo-blood group antigens in their intestinal epithelium or mucosal secretions. 'Non-secretor' status has been associated with altered gut microbiota diversity, composition and function, although this association has not been universally replicated 105 , perhaps in line with the idea that the effect of the FUT2 genotype might be context dependent. The null FUT2 allele is associated with increased risk for T1D 106 and IBD
107
, mumps and several other autoimmune and infectious diseases 17, 108 but is protective against norovirus infection 109 and childhood ear infections 17 . The content and function of the microbiota can alter the lowmolecular-weight metabolites present in human blood 110 . Some bacterial metabolites, such as short-chain fatty acids, have widespread and important effects on many aspects of host biology, including immunological function, inflammation and risk of autoimmunity; for example, increased levels of short-chain fatty acids provide protection against autoimmune diabetes in the NOD ('nonobese diabetic') mouse model [111] [112] [113] [114] . Diminished microbial diversity has been observed in people with T1D 115, 116 , and alterations in the gut microbiota were observed in a small cohort of autoantibodypositive children who progressed to overt T1D 117 . In line with those findings, changes in the gut microbiome composition, known as 'dysbiosis' , accompanied by a decrease in blood and fecal shortchain fatty acids, have been reported to occur before the diagnosis of T1D [118] [119] [120] . Another study has linked the IL-2 pathway, which has a major role in autoimmune diabetes in both mice and humans, to alterations in the mouse and human gut microbiota 121 . Together with the loss in microbiome diversity caused by lifestyle changes associated with industrialization, these phenomena are thought to contribute to the continuous rise in the incidence of T1D [118] [119] [120] 122, 123 . This area is incredibly complex, with environmental factors dominating 8 , but one approach will be to identify which genes and their variants, such as FUT2, alter microbe-derived or microbe-modified circulating and intracellular metabolites in cases, control subjects and large-scale population cohorts.
While functional validation of candidate variants and genes has typically been challenging, the toolbox for functional genomics studies has expanded greatly in recent years with the addition of CRISPR-Cas9 methodologies, which now facilitate the study of endogenous gene function in physiological contexts, even in vivo. Of note, CRISPR-Cas9 techniques not only enable fine genome editing (the introduction of a variant of interest in a controlled genetic background or correction of specific mutations in patientderived cells) but also make possible upregulating or downregulating the expression of any gene of interest, within physiological parameters, by targeting to the relevant promoters a catalytically dead Cas9 endonuclease fused to either a transcriptional activator (CRISPRa) or a transcriptional repressor (CRISPRi). Similar techniques have also been employed to identify and validate which disease-associated SNPs fall within true, rather than predicted, regulatory regions 84 .
Unchartered regions
Even after the chromosome-conformation analyses, almost 20% of T1D-associated regions have no named candidate gene, often because the molecules encoded by the genes in the region do not ) or in both, as might be the case for TYK2 125, 126 . The discovery that GLIS3 is a causal gene for both T1D and T2D, encodes a transcription factor that regulates many genes expressed by β-cells, including the insulin-encoding gene, and influences Integration of PCHi-C data from 17 different blood cell types 78 with ImmunoChip 10 and imputed GWAS data 9 , using the COGS ('Capture Hi-C Omnibus Gene Score') method 78 , prioritized 97 previously unknown T1D candidate protein-coding genes and 39 non-coding transcripts. For clarity, we have limited the regions in the table to 29 T1D-associated regions in which new or previously nominated candidates were prioritized by PCHi-C (bold font) and to gene biotypes that were captured with sufficient coverage in the PCHi-C experimental design (from 90% of protein-coding transcripts to 50% of microRNAs, excluding non-coding biotypes, such as long intergenic noncoding RNAs with only 14% coverage). We used a threshold of 0.5 for the COGS gene score to prioritize genes on the basis of an integrative analysis of genetic association data and promoter-PIR contacts. However, if a region has strong LD and many SNPs associated with the disease, the posterior probability for each SNP to be causal is lowered, which attenuates the overall COGS gene score. For this reason, genes in such regions, such as the IL2-IL-21 region on 4q27, do not appear in this table, even though there are clear PIRs that overlap significant associations by GWAS (Fig. 1) . Currently, there are a total of 57 T1D regions, including the MHC listed in ImmunoBase (https://www.immunobase.org/disease/T1D/), plus one from an age-at-diagnosis analysis 34 , which results in a total of 58 regions as of February 2018. Gene annotations were derived from the Ensembl 75 (GRCh37) gene build 159 . We separated the table into columns showing T1D-associated regions, GRCh37 coordinates, genes previously assigned candidacy for T1D, previously unknown protein-coding genes and previously unknown non-coding RNAs prioritized by PCHi-C.
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β-cell apoptosis 127, 128 supports the possibility that the target tissue is an active driver of the disease 129 . One T1D-associated region, 17q21.31, that is also associated with the liver autoimmune disease primary biliary cirrhosis, is an example of a region with no immediately obvious candidate causal gene, at least in the context of the immune-cell-mediated β-cell destruction model, and illustrates the challenges facing researchers aiming to identify the causal genes 10, 130 . The T1D index SNP (rs1052553 A>G) lies within exon 9 of MAPT (which encodes the microtubule-associated Tau protein) and is a perfect tag of the two main haplotypes in the region [131] [132] [133] , H1 and H2, the latter of which is protective against Parkinson's disease and tauopathies 134 . H2 is also protective against T1D and primary biliary cirrhosis. There are nine protein-coding genes in this region, which comprises a megabase-long ancient inversion polymorphism and several copynumber variants and has over 2,100 SNPs in near perfect LD. Any one or more of the nine genes (or non-coding RNAs or transcripts) could be causal for T1D and primary biliary cirrhosis. However, in tauopathies (diseases characterized by the accumulation of hyperphosphorylated Tau protein), owing to the fact that rare, highly disease-penetrant mutations of MAPT have been identified, it is certain that MAPT is a causal disease gene in the region. The identities of the common causal variants in neurodegenerative disease remain uncertain, not least due to the high LD and the huge number of differences in the sequences of the two haplotypes 135 . eQTL analysis is also not very informative; not only are several of the genes in the wider MAPT region expressed in islets, but also analyses of human islets have revealed that several SNPs in the rs1052553 LD block act as islet eQTLs to increase expression of MAPT, MAPT-AS1, NSF, CRHR1 and KANSL1 and decrease expression of PLEKHM1 and ARL17A 136, 137 . Some of these lie in putative enhancer regions (rs55649944, rs111794853 and rs2732650) or predicted active transcription start sites (rs58879558) in islets. Of note, activation of CRHR1 (also known as CRFR1) has been proposed to promote β-cell proliferation, potentiate glucose-stimulated insulin secretion and protect against cytokine-induced β-cell death [138] [139] [140] . Nevertheless, MAPT could be a causal factor; therefore, a first step is to determine if the protein it encodes, Tau, and its pathogenic form, hyperphosphorylated Tau, are present in pancreatic β cells. Two reports have suggested that Tau is expressed in human islets and in a rat β-cell line 141, 142 , findings supported by evidence in the Human Protein Atlas (https://www.proteinatlas.org/), results from a transgenic mouse model 143 and our own evidence of detectable expression of Tau protein in human β-cells and not islet α-cells (M.I.S. and J.A.T., unpublished observations). Despite originating in different germ layers, pancreatic β-cells and neurons show many similarities in their cell biology and developmental programs 144 , including the transcription factor GLIS3 145 . In addition, both cell types are considered post-mitotic, with very limited to no regenerative capacity, which renders them both vulnerable to the effects of misfolded, aggregated proteins and endoplasmic-reticulum stress 146, 147 . We propose that common cellular mechanisms underlie the fragility of β-cells in T1D and T2D and that of dopaminergic neurons in Parkinson's disease.
High-density interaction maps for the 17q21.31 region and its neighborhood, used in conjunction with information on chromatin states specifically derived from pancreatic islets, if not pure β-cell populations, will greatly assist efforts to pinpoint the causal variants and genes that drive the associations with T1D. However, caution should be exercised in excluding variants or genes on the basis of information derived from non-diabetic islets or from islets carrying the benign allele. Stresses similar to those encountered in the pre-diabetic and diabetic pancreas can alter chromatin states dramatically, such that SNPs located within quiescent regions in the absence of disease might map to active regions in tissues from diseased people.
Concluding remarks
Understanding the genetic basis of the biological pathways and processes underlying the etiology of autoimmune diseases has the potential to improve the success rate and safety of drugs 148 and has raised the possibility of repositioning and repurposing of approved drugs 149 such as recombinant IL-2 (aldesleukin) [150] [151] [152] [153] . As data from an increasing number of sources become widely available, the opportunity to integrate these data together becomes possible. Each autoimmune disease-related region in the genome can now be examined and fine mapped to obtain the small number of SNPs that most probably cause the increase in disease susceptibility; to identify the most likely cell type driving this association through determining which of these SNPs lie in functional regions of which cell type; and to highlight, through eQTL and chromatin contact experiments, the genes these SNPs are most probably regulating. This not only will help in the understanding of autoimmune diseases but also can point to potential therapeutic pathways for drug development. In parallel, considerable efforts to define the functions of the human immune system 154, 155 and pancreatic islets 156 in health and disease will converge and greatly accelerate not only understanding of the primary causes of common diseases but also the ability to stratify patients recruited into drug trials and to explain why some patients respond, while others do not, or relapse 157, 158 .
